NCT04766177RecruitingPhase 3
Role of Bumetanide in Treatment of Autism
Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children
Source: ClinicalTrials.gov · Last updated 23 Feb 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Role of bumetanide in Autism
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 19 Feb 2021
- Start date
- Jan 2021
- Primary completion date
- Dec 2030
- Lead sponsor
- Sherief Abd-Elsalam
- Diseases
- Autism
- NCT number
- NCT04766177
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 80
- From Jan 2021 to the primary completion date, Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).
Who the study is looking for
- All patients with ASD diagnosed by CARS rating Scale⩾30.
- Age of patients range between (3-12) years.
Age in the registry: 3 years to 12 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sherief Abd-Elsalam Coordinator of this site? Confirm its status | Tanta | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.